CMS: Medicaid NPRM Aims to Foster VBP Models for Prescription Drugs
FDA Approves Pembrolizumab for Treatment of TMB-H Solid Tumors
FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC
FDA Approves HPV Vaccine Gardasil 9 for Prevention of Certain Head & Neck Cancers
FDA Approves Pegfilgrastim-apgf) Biosimilar to Pegfilgrastim
FDA Approves Nivolumab for Previously Treated Advanced Esophageal SCC
ASTRO Releases New Clinical Guideline for RT to Treat Nonmetastatic Cervical Cancer
CMMI Adds New Flexibilities & Adjustments to Oncology Care Model
FDA Approves Atezolizumab + Bevacizumab for Previously Untreated Advanced HCC
FDA Approves Ramucirumab + Erlotinib for First-Line Treatment of Metastatic NSCLC
FDA Approves Nivolumab+Ipilimumab Combo as 1st Line Treatment for Metastatic NSCLC
FDA Approves Brigatinib for ALK-Positive Advanced NCSLC
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
FDA Approves Ripretinib for Previously Treated Advanced GIST
FDA Approves Rucaparib for Pretreated BRCA-Mutated mCRPC
FDA Approves Nivolumab + Ipilimumab Combination for Metastatic NSCLC
FDA Grants Accelerated Approval to Pomalidomide for Karposi Sarcoma
FDA Approves Olaparib + Bevacizumab as Maintenance Treatment for Advanced Ovarian Cancer
FDA Approves Selpercatinib for Lung & Thyroid Cancers with RET Mutations or Fusions
FDA Approves Capmatinib for Adults with Metastatic NSCLC
NAM to Host Webinar on Supporting Clinician Well-Being During COVID-19
FDA Issues Emergency Use Authorization for Remdesivir for Severe COVID-19
CMS Issues Sweeping Regulatory Waivers & Changes to Further Expand Telehealth Options
FDA Approves Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
FDA Approves Niraparib for Frontine Maintenance of Advanced Ovarian Cancer
CMS Re-evaluating Accelerated Payment Program; Halting Advance Payment Program
President Trump Signs $484 Billion Coronavirus Relief Package
House Passes Coronavirus Rescue Funding Package Totaling Nearly $500 Billion
CMS Launches COVID-19 Workforce Virtual Toolkit
FDA Approves Sacituzumab Govitecan-hziy in Previously-Treated Metastatic Triple Negative Breast Cancer
